[Federal Register Volume 81, Number 219 (Monday, November 14, 2016)]
[Notices]
[Page 79508]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-27222]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious 
commercialization of federally-funded research and development. Foreign 
patent applications are filed on selected inventions to extend market 
coverage for companies and may also be available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the U.S. patent applications listed below may be obtained by writing to 
the indicated licensing contact at the National Heart, Lung and Blood 
Institute, Office of Technology Transfer and Development, National 
Institutes of Health, 31 Center Drive, Room 4A29, MSC2479, Bethesda, MD 
20892-2479; telephone: 301-402-5579. A signed Confidential Disclosure 
Agreement may be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: Technology descriptions follow.

Immortalized Organ of Corti Cell Line OC-k3 Description of Technology

    Available for nonexclusive licensing as a research material is a 
conditionally immortalized Organ of Corti cell line called OC-k3. 
Sensory cells from the auditory organ, the Organ of Corti, are 
terminally differentiated and cannot be cultured. Moreover, few of them 
can be isolated per cochlea and survive only few hours after isolation 
making impossible to use on them many biochemical and molecular biology 
techniques. OC-k3, expresses many markers of sensory cells and it has 
already been used as an in vitro model for a variety of studies.

Potential Commercial Applications

 Research
 Hearing research
 Susceptibility to ototoxic drugs

Development Stage

 Materials
    Inventors: Gilda Mabel Canseco de Kalinec and Federico Kalinec 
(both of NIDCD).

Publications

    1. Bertolaso L, et al. (2001) ``Apoptosis in the OC-k3 immortalized 
cell line treated with different agents.'' Audiology 40:327-335. PMID: 
1178104637-5745.
    2. Previati M, et al. (2007) ``Cisplatin cytotoxicity in Organ of 
Corti-derived immortalized cells.'' J Celt Biochem.101(5):1185-97, 
PMID: 7243113.
    Intellectual Property: HHS Reference No. E-012-2017/0--Research 
Material.
    Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; 
[email protected].

    Dated: November 7, 2016.
Michael Shmilovich,
National Heart, Lung and Blood Institute, Office of Technology Transfer 
and Development, National Institutes of Health.
[FR Doc. 2016-27222 Filed 11-10-16; 8:45 am]
 BILLING CODE 4140-01-P